CJC-1295: The Complete Guide
A powerful, longer-lasting GHRH peptide — and the source of the most common confusion in this whole category: DAC vs No-DAC. Here's everything explained clearly.
This guide summarizes published research on CJC-1295. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
CJC-1295 is one of the most popular growth-hormone peptides — and also one of the most misunderstood, because it comes in two very different forms that behave almost like separate compounds. Get that distinction right and CJC-1295 is straightforward; get it wrong and you'll either waste product or over-stimulate your system. This guide makes it clear.
We'll cover what CJC-1295 is, how it works, the all-important DAC vs No-DAC difference, the benefits, how each form is dosed, why it's so often paired with Ipamorelin, and an honest look at safety and evidence.
What CJC-1295 Is
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — the natural hormone your hypothalamus uses to tell your pituitary to release growth hormone. Like sermorelin, it's built on the GHRH(1-29) fragment (the active core of the 44-amino-acid natural hormone). But CJC-1295 adds a clever upgrade: four amino-acid substitutions that protect it from DPP-IV, the enzyme that normally destroys natural GHRH within minutes.
The result is a GHRH peptide that's far more stable and longer-lasting than the natural hormone (or than sermorelin). It belongs to the "Door 1" family of GH peptides — the GHRH analogs — which amplify your natural GH-releasing signal. (For the full two-pathway picture, see our pillar on how growth hormone peptides work.)
How It Works
CJC-1295 is a true secretagogue — it prompts your body to release its own growth hormone rather than supplying it from outside. The chain is simple:
1. Binds the GHRH Receptor
CJC-1295 binds the GHRH receptor on your pituitary's somatotroph cells — the same receptor your natural GHRH uses.
2. Stimulates GH Release
This prompts the pituitary to synthesize and release growth hormone — amplifying its output.
3. The Liver Makes IGF-1
The released GH signals your liver to produce IGF-1, which carries out most of GH's downstream effects.
4. Effects Build Over Time
With consistent use, the sustained or repeated GH pulses drive benefits that accumulate over weeks and months.
The stability upgrade is what makes CJC-1295 distinctive: because it resists breakdown, it keeps signaling the pituitary far longer than natural GHRH — and how much longer depends entirely on which form you're using.
DAC vs No-DAC: The Distinction That Defines It
This is the single most important thing to understand about CJC-1295. It comes in two forms that share the same active peptide but behave completely differently, because of one added component: the DAC (Drug Affinity Complex).
| CJC-1295 without DAC (Mod GRF 1-29) | CJC-1295 with DAC | |
|---|---|---|
| The difference | No albumin-binding group | Binds to albumin in the blood |
| Half-life | Short (~30 minutes) | Long (~6–8 days) |
| GH pattern | Sharp, natural pulses | Sustained elevation over days |
| Dosing | Multiple times daily | Once or twice weekly |
| Usually used | Stacked with a GHRP (Ipamorelin) | Standalone |
| Best for | Natural pulsatility, feedback preserved | Convenience, sustained levels |
How the DAC actually works
The DAC is a small reactive group that lets the peptide covalently bind to albumin — a long-lived protein in your blood — within minutes of injection. Since albumin sticks around for weeks, this essentially turns CJC-1295 into a slow-release depot: one injection keeps signaling your pituitary for nearly a week. In a clinical study, a single dose of CJC-1295 with DAC produced elevated GH for six days or more and elevated IGF-1 for nine to eleven days. Without the DAC, the peptide clears in about 30 minutes, producing one sharp pulse — which is why the No-DAC version is dosed multiple times a day.
The most common mistake in GH peptide dosing
Confusing the two forms — or dosing one on the other's schedule — is genuinely the most common error people make. Injecting a DAC dose on a No-DAC schedule (multiple times daily) can overwhelm the pituitary with continuous stimulation and pile on side effects; dosing No-DAC weekly wastes it entirely. Always know exactly which form you have and use its matching protocol. If you're unsure which your product is, check before dosing.
Benefits & What to Expect
Both forms ultimately raise GH and IGF-1, so the benefits are similar — those of improved growth-hormone signaling:
Better Sleep
Often an early, noticeable effect — deeper, more restorative sleep, reflecting GH's tie to slow-wave sleep.
Body Composition
Gradual fat reduction and improved muscle tone, typically over 2–3 months of consistent use.
Recovery & Energy
Improved recovery from training and better daytime energy as GH signaling improves.
Skin & Anti-Aging
Support for skin quality and general vitality — part of the broader anti-aging appeal.
As with all GH peptides, expect gradual changes over months, not dramatic transformation. Consistency is what delivers results.
Dosing Each Form
The two forms require entirely different approaches. The following is a general informational reference, not a medical recommendation.
| Aspect | No-DAC (Mod GRF 1-29) | With DAC |
|---|---|---|
| Typical dose | ~100 mcg per injection | ~1–2 mg per week |
| Frequency | 1–3× daily | Once or twice weekly |
| Timing | Empty stomach; bedtime / post-workout | Consistent weekly day |
| Pairing | Usually with Ipamorelin | Usually standalone |
The "saturation dose" — why 100 mcg is the number
For the No-DAC form, about 100 mcg is the saturation dose — the point where your pituitary's GHRH receptors are essentially fully occupied. Going higher gives diminishing returns: jumping from 100 mcg to 300 mcg might increase GH output by only ~20–30%, not triple it. This is precisely why the standard approach is to dose ~100 mcg more frequently (more pulses), and why stacking with Ipamorelin — which opens a second pathway — is far more effective than simply using more CJC-1295.
Both forms come as lyophilized powder, reconstituted with bacteriostatic water. See our reconstitution guide, dosing basics, and tropical storage guide (peptides are heat-sensitive — and DAC peptides especially dislike freeze-thaw cycles).
Stacking With Ipamorelin
CJC-1295 (especially the No-DAC form) is most famously paired with Ipamorelin — this is the classic GH peptide stack. The logic is elegant: CJC-1295 works through the GHRH pathway (telling the pituitary to make GH), while Ipamorelin works through a separate ghrelin-receptor pathway (telling it to release GH and lifting the somatostatin brake). Because they hit two different receptors, together they produce a substantially larger GH pulse than either alone.
Which form to stack
The No-DAC form is the one designed for stacking — its short pulse matches Ipamorelin's timing, preserving natural pulsatility. The DAC form is generally used standalone, because its sustained elevation already provides continuous stimulation, and adding a GHRP on top can lead to excessive GH exposure and more side effects. We cover the pairing in depth in our CJC-1295 + Ipamorelin stack guide.
Side Effects
CJC-1295's side effects are generally mild and typical of GH peptides:
- Injection-site reactions — redness, itching, or minor irritation (most common)
- Water retention — mild fluid retention, more noticeable with the sustained DAC form
- Flushing or headache, occasionally, shortly after injecting
- Numbness or tingling — uncommon, more likely at higher doses
Because it raises GH and IGF-1, the relevant monitoring is for the effects of higher GH — blood sugar can rise, and IGF-1 is best kept within a sensible range rather than pushed indefinitely. Anyone using it should ideally monitor IGF-1 and metabolic markers with a provider.
CJC-1295 vs Sermorelin
Since both are GHRH analogs, people often compare them. The key difference is stability and duration.
| CJC-1295 | Sermorelin | |
|---|---|---|
| Structure | Modified GHRH(1-29), DPP-IV resistant | Plain GHRH(1-29) |
| Half-life | ~30 min (No-DAC) to 6–8 days (DAC) | Very short (~10–20 min) |
| Duration of effect | Longer, more sustained | Brief, sharp pulse |
| Best for | Stronger/sustained GH support | Gentle, natural pulsatility |
Think of CJC-1295 as a more stable, longer-lasting evolution of the sermorelin concept. For a three-way comparison including tesamorelin, see our Sermorelin vs CJC vs Tesamorelin guide, and our Sermorelin complete guide.
Safety & Regulatory Status
CJC-1295 is generally reported to be well tolerated, but honest context matters.
What to know before considering it
CJC-1295 is not FDA-approved and is sold as a research compound. It reached Phase 2 development (for HIV lipodystrophy) in 2006, which was halted, and no modern late-stage human trials are registered — so long-term human safety data is limited. Its compounding status in 2026 has been less favorable than some other peptides. Because it raises GH and IGF-1, it warrants real caution in anyone with a history of cancer (IGF-1 can theoretically promote cell growth), can affect blood sugar, and requires a functioning pituitary to work. It's also banned year-round by WADA, so tested athletes must avoid it. Anyone with a history of cancer, diabetes, or a pituitary condition should consult a doctor first. See our when to consult a doctor guide.
Common Questions
What is CJC-1295 used for?
CJC-1295 is used to stimulate the body's own growth-hormone production, most commonly for anti-aging goals, improved sleep, recovery, and gradual body-composition support (fat reduction and muscle tone). It's a GHRH analog that amplifies your natural GH-releasing signal. It's especially popular stacked with Ipamorelin, which adds a second GH-release pathway for a larger combined effect.
What's the difference between CJC-1295 with DAC and without DAC?
It's the single most important distinction. With DAC, the peptide binds to albumin in your blood, extending its half-life to about 6–8 days — producing sustained GH elevation and dosed weekly, usually standalone. Without DAC (Mod GRF 1-29), it clears in about 30 minutes, producing sharp natural pulses, dosed multiple times daily, and usually stacked with Ipamorelin. They share the same active peptide but behave like different compounds — so you must know which you have and use its matching protocol.
Which is better, DAC or No-DAC?
Neither is universally better — it depends on your goal. No-DAC produces natural pulses that preserve your body's feedback rhythm, and is designed to be stacked with Ipamorelin (the classic pulsatile protocol), but requires daily dosing. DAC offers convenience (weekly dosing) and sustained GH elevation, but its continuous stimulation is a different physiological signal and can cause more water retention. No-DAC suits those prioritizing natural pulsatility; DAC suits those prioritizing convenience.
How much CJC-1295 should be used?
For the No-DAC form, about 100 mcg per dose is standard — this is the "saturation dose" where the pituitary's receptors are essentially full, so going higher gives diminishing returns (100 to 300 mcg might add only 20–30% more GH). It's dosed 1–3 times daily. The DAC form is dosed differently — roughly 1–2 mg once or twice weekly. This is general information, not a prescription; actual dosing should be worked out with a knowledgeable healthcare professional.
Why is CJC-1295 usually combined with Ipamorelin?
Because they work through two different pathways, so together they're greater than the sum of their parts. CJC-1295 (a GHRH analog) tells the pituitary to make GH; Ipamorelin (a GHRP) tells it to release GH and lifts the somatostatin brake. Firing both at once produces a much larger GH pulse than either alone. Since raising CJC-1295 above its saturation dose gives little extra, adding Ipamorelin's separate pathway is far more effective than just using more CJC-1295.
How is CJC-1295 different from sermorelin?
Both are GHRH analogs, but CJC-1295 is modified with amino-acid substitutions that resist enzymatic breakdown, making it more stable and longer-lasting. Sermorelin has a very short half-life (~10–20 min) and a brief, gentle pulse; CJC-1295 No-DAC lasts a bit longer (~30 min), and CJC-1295 with DAC lasts days. Think of CJC-1295 as a more stable, longer-lasting evolution of the sermorelin concept.
Is CJC-1295 safe?
It's generally reported as well tolerated, with mild side effects (injection-site reactions, some water retention, occasional flushing or tingling). But it's not FDA-approved, its Phase 2 development was halted, and long-term human safety data is limited. Because it raises GH and IGF-1, it warrants caution in anyone with a cancer history, can affect blood sugar, needs a functioning pituitary, and is WADA-banned. Monitoring IGF-1 and metabolic markers with a provider is wise.
Is CJC-1295 legal in Costa Rica?
CJC-1295 is sold as a research compound in Costa Rica, the same framework used in most countries with active peptide markets, for laboratory and research purposes. Buying locally avoids the heat exposure that international shipping puts delicate, heat-sensitive GH peptides through. See our FAQ page for more.
Questions about CJC-1295?
Whether you want help understanding DAC vs No-DAC, how it stacks with Ipamorelin, or how it compares to sermorelin, we're happy to help — honestly, including the limits of the evidence. We answer every message personally, with no pressure and no upsell.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. CJC-1295 is not approved by the FDA or Costa Rica's Ministerio de Salud as a treatment for any condition; it is sold as a research compound intended for laboratory and scientific study, not as a substitute for prescribed, medically supervised treatment. Its Phase 2 development was halted, and long-term controlled human safety data is limited. CJC-1295 raises growth hormone and IGF-1, can affect blood sugar, requires a functioning pituitary, and is prohibited in competitive sport by WADA. It should be avoided in active cancer or a history of certain cancers, and in pregnancy. Always consult a qualified healthcare professional before beginning any peptide protocol, especially if you have a medical condition or take medications. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- Journal of Clinical Endocrinology & Metabolism (Teichman et al., 2006): CJC-1295 — sustained GH and IGF-1 elevation after single and multiple doses in healthy adults.
- Journal of Medicinal Chemistry (Alba et al., 2006): DPP-IV-resistant GHRH(1-29) analogs and CJC-1295 in GHRH-knockout mice.
- NCBI/PMC (Jette et al., 2005): CJC-1295 identified as a long-lasting GRF analog via albumin binding.
- Endocrine (Ionescu & Ghigo): Saturation dosing of GHRH analogs and the pituitary GH-response ceiling.
- NCBI/PMC: GHRH-receptor signaling, pulsatile vs sustained GH release, and DAC albumin-binding pharmacokinetics.
- World Anti-Doping Agency (WADA): Prohibited List — growth-hormone secretagogues.
- Nature Reviews Drug Discovery: "Therapeutic peptides: current applications and future directions."
